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Here we present new and original data on the endogenous con-
version of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans
and its effects on the cardiovascular system. A randomized,
crossover, controlled clinical trial was performed with individuals
at cardiovascular risk (n ¼ 33). They received white wine (WW)
(females 1, males 2 standard drinks/day), WW plus Tyr capsules
(WW þ Tyr) (25mg Tyr capsule, one per WW drink), and water
(control) ad libitum. Intervention periods were of 4 weeks pre-
ceded by three-week wash-out periods. We assessed the conver-
sion of Tyr to OHTyr, its interaction with a polygenic activity score
(PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on
cardiovascular risk markers. For further details and experimental
findings please refer to the article “Cardiovascular benefits of
tyrosol and its endogenous conversion into hydroxytyrosol in
humans. A randomized, controlled trial” [1].
© 2019 The Author(s). Published by Elsevier Inc. This is an open
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Thirty-three participants (21 men and 12 women) were randomly allocated to participate in a
clinical trial, and 32 participants completed the trial. Initially, 192 subjects were assessed for eligibility,
157 were excluded for 1) not meeting the inclusion criteria, 2) refusing to participate, 3) taking
medication non compatible with the interventions, 4) suffering from a coronary heart disease, 5)
having undergone bariatric surgery, 6) intestinal alterations, 7) mobility problems, 8) chronic in-
flammatory diseases, 9) dysregulated hypertension, 10) illicit drug consumption, 11) heavy alcohol
consumption, and 12) hepatic alterations. The 33 volunteers were randomly allocated to receive the
following treatments for 4 weeks: WW, WW þ Tyr and control intervention [1] (Fig. 1).
Baseline characteristics of the participants are shown in Table 1. No dietary differences were
observed among interventions (Table 2). Volunteers were genotyped for multiple allelic variants of
CYP2A6 and CYP2D6 (Table 3). For each enzyme, an activity scorewas given to each volunteer according
to the alleles identified (Table 4). A pooled polygenic activity score (PAS) was calculated by adding the
two activity scores together.
On the basis of PAS, 11 individuals were categorized as low (LA, PAS range: 1e2.5), 19 as normal (NA,
PAS range: 3e4), and 2 as rapid (RA, PAS range¼ 5) activity metabolizers. Due to their low number, RAs
were excluded for analyses. Age and gender were equally distributed among the three groups. The
conversion of Tyr into OHTyr was assessed by measuring OHTyr and Tyr urinary recovery following
each treatment. No changes were observed in lipid biomarkers (Table 5) with exception of HDL-
cholesterol (HDLc) which increased after WW and WW þ Tyr. HDL-c increased in a dose-dependent
manner with the content of alcohol plus Tyr administered in all participants (p ¼ 0.027 for linear
trend), among men (p ¼ 0.001 for linear trend), and with a borderline significance in the NA group
(p ¼ 0.082) (Fig. 2). Endothelin-1 levels at the end of WW þ Tyr were lower than at the end of WW
intervention (Table 6). Table 7 outlines the transcriptomic changes observed in genes related with
endothelial function. Changes are grouped by sex and PAS. Fig. 3 compares the effects observed inWW
and WW þ Tyr intervention.Fig. 1. Schema of the clinical trial. Intervention periods of 4 weeks. WO: wash-out period (3 weeks) without alcohol and following a
low-phenolic content diet. WW (white wine): 2 glasses (270 mL, 27 g of alcohol, 2.8 mg of Tyr and 0.4 mg of OHTyr) for men, and 1
glass (135 mL, 13.5 mg, 1.4 mg of Tyr, and 0.2 mg of OHTyr) for women. WW þ Tyr (white wine plus tyrosol): 2 glasses of wine: 270
mL, 27 g of alcohol, 2.8 þ 50 mg of Tyr (2 capsules), and 0.4 mg of OHTyr for men, and 1 glass:135 mL, 13.5 g of alcohol, 1.4 mg þ 25
mg of Tyr (1 capsule), and 0.2 mg of OHTyr for women.
Table 1
Baseline characteristics of the participants.
Variable Values




BMI, kg/m2 32.6 ± 4.2
LDL cholesterol, mg/dL 118 ± 34.4
HDL cholesterol, mg/dL 50.2 ± 12.9
Total cholesterol, mg/dL 192 ± 39.3
Triglycerides, mg/dL 120 ± 72.2
Cardiovascular Risk factors, n (%)
Current smokers 6 (18.2%)
Family history of premature CHD 6 (19.4%)
Obesity (BMI  25kg/m2) 32 (97.0%)
Type 2 Diabetes 13 (39.4%)
Hypertension 28 (84.8%)
High LDL cholesterol (>130 mg/dL) 25 (75.6%)
Low HDL cholesterol (<40 mg/dL for men or <50 mg/dL for women) 8 (24.2%)
Medications, n (%)
Alfa blockers 2 (6.1%)
Beta blockers 6 (18.2%)
ACE inhibitors 14 (42.4%)
Angiotensin II receptor antagonists 11 (33.3%)
Diuretics 13 (39.4%)
Statins 16 (48.5%)
Oral hypoglycemic drugs 12 (36.4%)
Acetylsalicylic acid 10 (30.3%)
Data presented as mean ± SD or n (%) (n ¼ 33). BMI, body mass index; LDL, low density lipoproteins; HDL, high
density lipoproteins; CHD, coronary heart disease.
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2.1. Study design
A randomized, controlled, clinical trial with 33 individuals at cardiovascular risk (21 men and 12
women) was performed (Fig. 1). Inclusion criteria were to be at high risk for coronary heart disease
(CHD) with 3 or more risk factors including: current smoking (>1 cig/day during the last month),
hypertension (140/90 mmHg or antihypertensive medication), high LDL cholesterol (>130 mg/dl or
lipid-lowering therapy), low HDL-cholesterol (40 mg/dl in men and 50 mg/dl in women), over-
weight/obesity (body mass index 25 kg/m2), a family history of premature CHD, and/or type II dia-
betes treated with oral hypoglycemic agents; and to have a social or recreational use of ethanol/wine
consumption at least once during lifetime. Exclusion criteria were participants with a history of car-
diovascular disease or severe chronic illness, chronic inflammatory diseases, BMI > 40 kg/m2, suffered
from any severe illness or undergonemajor surgery in the last threemonths prior to the clinical trial, an
alcohol consumption exceeding 8 units or 80 g per day, a history of alcohol hypersensitivity/intoler-
ance, illicit drug consumption, intake of antioxidant supplement(s), the taking of sedative drugs that
could potentially interact with alcohol, multiple allergies or intestinal diseases, being vegetarian of
following special diets, a history of food allergies or intolerances, illiteracy, and any condition that
limited mobility making trial visits impossible or worsening adherence to treatments.
Participants were asked to follow a controlled diet with a moderate content of antioxidants and to
abstain of any alcoholic drinks (except in the framework of treatment allocations) thorough the trial.
The consumption of certain food was limited to a maximum of 1) vegetables (including pulses): one
serving/day, 2) fruits (or juices): 2 pieces/day, 3) ordinary olive oil: maximum 25 mL/day, 4) drinks
containing xanthines (coffee, tea, cola, energy drinks …): maximum 3 cups/day, 5) chocolate:
Table 2
Energy, nutrients, and fiber at the beginning and at the end of the clinical trial.
Variable Treatment P*
Control P WW P WWþTYR P
Energy, kcal/day
Baseline 1695 ± 446 1663 ± 421 1624 ± 370 NS
12-week 1643 ± 361 0.616 1650 ± 354 0.868 1737 ± 450 0.082
HC, % energy
Baseline 38.2 ± 8.6 40.2 ± 6.4 38.8 ± 6.3 NS
12-week 38.3 ± 7.3 0.906 37.6 ± 7.7 0.095 37.8 ± 7.5 0.360
HC, grams
Baseline 159 ± 48 165± 43 157 ± 38 NS
12-week 156 ± 41 0.811 153 ± 40 0.209 163 ± 45 0.532
Protein, % energy
Baseline 20.9 ± 4.0 19.2 ± 3.0 21.5 ± 4.5 NS
12-week 21.2 ± 4.1 0.578 19.5 ± 4.8 0.028 19.0± 3.9 0.142
Protein, grams
Baseline 88 ± 25 79 ± 19 86 ± 24 NS
12-week 87 ± 25 0.939 81 ± 30 0.651 82 ± 23 0.184
Total Fat, % energy
Baseline 40.7 ± 7.5 40.3 ± 6.2 39.2 ± 6.6 NS
12-week 40.2 ± 7.2 0.625 36.7 ± 9.0 0.496 38.6 ± 6.3 0.230
Total Fat, grams
Baseline 78 ± 29 76 ± 28 72 ± 24 NS
12-week 74 ± 23 0.489 68 ± 24 0.015 76± 28 0.809
SFA, % energy
Baseline 11.4± 3.8 10.1 ± 3.0 11.4 ± 4.2 NS
12-week 10.7 ± 3.7 0.526 10.1 ± 3.9 0.953 10.4 ± 3.7 0.272
SFA, grams
Baseline 22 ± 12 19 ± 9 21 ± 12 NS
12-week 20 ± 10 0.428 19 ± 10 0.873 21 ± 11 0.855
MUFA,% energy
Baseline 19.8 ± 5.0 19.7 ± 4.2 18.6 ± 5.0 NS
12-week 20.1 ± 4.2 0.893 18.4 ± 5.1 0.177 19.6 ± 3.5 0.172
MUFA, grams
Baseline 53.3 ± 21.0 53.8 ± 15.5 53.0 ± 16.6 NS
12-week 51.9 ± 21.2 0.475 46.5 ± 13.3 0.274 50.0 ± 14.3 0.054
PUFA, % energy
Baseline 6.1 ± 2.6 6.8 ± 2.5 6.0 ± 2.1 NS
12-week 5.9 ± 2.3 0.697 5.2 ± 2.1 0.222 5.4 ± 1.9 0.179
PUFA, grams
Baseline 12 ± 6 13 ± 8 11 ± 4 NS
12-week 11 ± 7 0.901 10 ± 5 0.025 11 ± 6 0.960
Fiber, g/day
Baseline 20 ± 7 23 ± 11 20 ± 8 NS
12-week 20 ± 8 0.894 23 ± 11 0.848 21 ± 9 0.408
Dietary data is expressed as mean ± SD (N ¼ 32). HC, carbohydrates; SFA, saturated fatty acids; MUFA, monounsaturated fatty
acids; PUFA, polyunsaturated fatty acids. P Intra-treatment comparisons by Student's t-test. *P value for ANOVA repeated
measures adjusted by age and sex.
A. Boronat et al. / Data in brief 27 (2019) 104787 5maximum one piece (small 15 gr)/day, 6) nuts: maximum 30 g (a small handful)/week, and 7) fish:
maximum 3 times per week (150 g/serving).
During the control intervention participants were allowed to only drink water (no alcohol. wine or
supplemented Tyr or OHTyr). The reason for different WW doses for men and women was in order to
follow the American Heart Association (AHA) guidelines, which limit alcohol consumption to one drink
in women and two in men, preferably taken at meals [2]. The doses of wine administered are within
those recommended by the AHA.
A 24 h food recall was performed to assess dietary intake before and after each intervention period.
Physical activity was recorded at the beginning and end of the clinical trial and assessed by the
Minnesota Leisure Time Physical Activity Questionnaire, validated for the Spanish population [3].
Table 3
Characteristics of CYP2A6 and CYP2D6 SNPs tested.
Tested Allelic Variants Reference Number Nucleotide Substitution Amino acid substitution TaqMan Assay ID
CYP2A6 rs1801272 479T > A Leu160His C_27861808_60
rs28399433 - 48T > G Upstream C_30634332_10
CYP2D6 rs1135840 4181G > C Ser486Thr C_27102414_10
rs16947 2851C > T Arg296Cys C_27102425_10
rs3892097 1847G > A Intron Variant C_27102431_DO
rs5030656 2616_2618delAAG Lys281del C_32407229_60
rs1065852 100C > T Pro34Ser C_11484460_40
rs769258 31G > A Val11Met C_27102444_80
rs28371725 2989G > A Intron Variant C_34816116_20
Table 4
Activity score assigned to each tested variant in the PAS model.
Tested Allelic Variants Functional consequence Activity score Defining SNP
CYP2A6 *2 No function 0 479T > A
*4 No expression 0 Gene deletion
*9 Decreased þ0.5 - 48T > G
*12 Decreased þ0.5 Hybrid allele with CYP2A7
*1xN Increased þ2 Multiple copies
CYP2D6 *2 Normal þ1 2851C > T
4181 G > C
*4 No function 0 1847 G > Aa
*5 No expression 0 Gene deletion
*9 Decreased þ0.5 2616 del AGG
*10 Decreased þ0.5 100C > T
4181 G > C
*35 Normal þ1 31G > A
2851C > T
4181 G > C
*41 Decreased þ0.5 2989 G > A
2851C > T
4181 G > C
*1xN Increased þ2 Multiple copies
*2xN
*35xN
a *4 sub-alleles can commonly present other SNPs such as 100C > T, 4181 G > C and/or 2851C > T.
Table 5
Changes in lipid and inflammatory biomarkers (mg/dL).
Interventions
Control WW WW þ TYR P value for WW þ Tyr
vs Control vs WW
Total Cholesterol 1.8 ± 12.5 2.9 ± 21.8 7.7 ± 24.4 0.665 0.753
LDL cholesterol 1.0 ± 14.1 0.1 ± 17.8 4.7 ± 22.3 0.511 0.761
Triglycerides 14.7 ± 62.0 6.0 ± 25.9 0.9 ± 25.7 0.290 0.788
Glucose 0.9 ± 13.4 2.7 ± 10.3 2.6 ± 12.0 0.849 0.999
hsCRP 0.2 ± 1.3 0.02 ± 0.3 0.01 ± 0.2 0.443 0.516
Changes expressed as mean ± SD (N ¼ 32). LDL, low density lipoprotein; hsCRP, high sensitivity C reactive protein. ANOVA
adjusted by age, sex and smoking habits, LDL cholesterol at the beginning of the clinical trial, and baseline levels.
A. Boronat et al. / Data in brief 27 (2019) 1047876A general physical examination, and routine urine, blood chemical and hematological analyses, were
performed at the beginning and end of the trial. Blood and 24h-urine samples were collected at fasting
state before and after each intervention period. Blood was collected into 10 mL tubes containing EDTA
and centrifuged (1700g, 15 min, 4 C), and plasma and buffy coat samples were then isolated. Pe-
ripheral blood mononuclear cells (PBMC) were isolated using a Vacutainer Cell Preparation Tube
Fig. 2. Changes in HDL cholesterol (HDL-c) after interventions. Change in HDL-c compared to the baseline of the intervention
expressed as mean and SD in all participants (A), only men (B) and only normal activity metabolizers (C). ANOVA adjusted by age, sex
and smoking habits, LDL cholesterol at the beginning of the clinical trial, and baseline levels * P < 0,05; **P < 0,01.
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Table 6
Endothelin concentrations (ng/dL) after interventions.
Interventions
Control WW WW þ TYR P value for WW þ Tyr
vs Control vs WW
All participants 2.15 ± 0.90 2.33 ± 1.07 2.03 ± 0.82 0.572 0.031
Women 2.38 ± 1.07 2.57 ± 1.11 2.12 ± 0.81 0.479 0.108
Men 2.01 ± 0.80 2.16 ± 1.08 1.99 ± 0.87 0.990 0.463
Genotype interaction
LA 1.93 ± 0.69 2.25 ± 0.96 1.89 ± 0.72 0.981 0.203
NA 2.24 ± 0.95 2.48 ± 1.32 2.13 ± 1.07 0.747 0.068
Endothelin-1 concentrations are expressed as mean ± SD (N ¼ 32). WW, white wine; WW þ Tyr, white wine plus tyrosol (Tyr)
capsules; LA, low activity group metabolizers; NA, normal activity group metabolizers. ANOVA adjusted by age, sex, smoking,
acetylsalicylic acid consumption, and baseline levels. *P < 0.05 versus its baseline; P value, significance for inter-intervention
comparisons.
A. Boronat et al. / Data in brief 27 (2019) 1047878(CPT™) and kept for RNA extraction. Plasma, urine, and PBMC samples were frozen at 80 C until
analysis. Genomic DNA isolation from buffy coat was performed with QIAamp DNA Blood Midi Kit
(Qiagen, Dusseldorf, Germany).
2.2. Tyr and OHTyr metabolites analysis
The urinary concentrations of Tyr and OHTyr metabolites were determined from samples collected
before and after each intervention following a validated methodology [4]. Briefly, 0.5 mL of urine was
diluted with 0.5 mL of purified water, spiked with 10 mL of internal standard mixture (containing 10
mg/mL of 3-(4-hydroxyphenyl)-1-propanol, 3-(4-hydroxyphenyl)-1-propanol glucuronide and 10 mg/
mL HT-10-O-sulfate) and stabilized with 1 mL of phosphoric acid 4%. Thereafter, samples went under a
solid-phase extraction using Oasis HLB columns 3 mL, 60-mg cartridges from Waters Corporation
(Milford, MAUSA). First, samples were loaded into cartridges thenwashed with 2 mL of purified water.
Thereafter, the compounds of interest were eluted from the cartridge with 2 mL of pure methanol. The
methanol extracts were then evaporated until dryness under a stream of nitrogen (29 C, 10e15 psi).
Finally, the dried extracts were reconstituted with a mixture of mobile phases (95% A and 5% B v/v),
transferred into HPLC microvials, and analyzed using LC-MS/MS. To prepare blank samples and cali-
bration curves, urine from volunteers after consuming a diet poor in Tyr and OHTyr- Tyr and OHTyr
metabolite concentrations were below quantification limits in these blank samples. Blank urine was
spiked with increasing concentrations of the metabolites of interest, and then processed in the same
manner as samples (described above). Identification and quantification of the metabolites was per-
formed using an Agilent 1200 series HPLC system coupled to a triple quadrupole (6410 Triple Quad
LC/MS) mass spectrometer with an electrospray interface from Agilent Technologies (Santa Clara, CA,
USA). For the chromatographic separation, an Acquity UPLC®BEH C18 column (100 mm  3.0 mm i.d.,
1.7 mmparticle size) fromWaters Corporation (Milford, MA, USA) was used at 40 C. The composition of
mobile phase A was 0.01% (v/v) formic acid in water, and mobile phase B was acetonitrile with 0.01%
(v/v) of formic acid. Injection volume was 10 mL and the flow rate was set at 0.25 mL/min. The ion
source operated in negative ionization for 27 minutes. Finally, urinary concentrations of each
metabolite were standardized with the total urinary excretion volume to obtain the total recovery of
each metabolite. Quantified Tyr metabolites included Tyr -4-sulfate and Tyr -4-glucuronide. OHTyr
metabolites quantified were OHTyr -3-sulfate, OHTyr-4-sulfate, OHTyr-acetate-3-sulfate, OHTyr-3-
glucuronide, OHTyr-4-glucuronide, and homovanillyl alcohol (HVAL)-4-glucuronide. Total Tyr and
total OHTyr correspond to the molar sum of their respective quantified metabolites.
2.3. Genotyping
Volunteers were genotyped for multiple allelic variants of CYP2A6 and CYP2D6 using TaqMan
genotyping assays (Applied Biosystems, Foster City, CA, USA) SNP genotyping was performed with a
Table 7
Transcriptomic changes (% change versus baseline) after interventions.
Intervention
Control WW WW þ Tyr P value for WW þ Tyr
vs Control vs WW
CD40L
All participants 8.9 ± 60.6 21.7 ± 62.3 26.8 ± 34.2y 0.042 0.003
Women 10.7 ± 75.4 28.8 ± 59.5 29.9 ± 33.7* 0.743 0.063
Men 24.6 ± 47.2 20.4 ± 66.2 25.5 ± 35.8* 0.016 0.024
Genotype interaction
LA 4.8 ± 66.7 11.1 ± 59.8 17.1 ± 35.6 0.874 0.514
NA 20.1 ± 60.0 16.7. ± 56.5 28.2 ± 33.9y 0.011 0.020
P65/RElA
All participants 1.1 ± 0.5 1.18 ± 0.5 0.9 ± 0.30 0.229 0.048
Women 7.6 ± 54.0 26.9 ± 63.3 16.9 ± 29.8 0.896 0.089
Men 22.9 ± 41.9 13.4 ± 48.2 2.2 ± 28.6 0.157 0.484
Genotype interaction
LA 16.7 ± 63.5 6.3 ± 45.3 3.0 ± 43.4 0.584 0.886
NA 6.7 ± 41.1 22.5 ± 58.3 -.12,5 ± 20.9 0.414 0.054
CFH
All participants 19.8 ± 57.6 28.8 ± 56.5* 9.1 ± 51.5 0.115 0.025
Women 9.2 ± 57.5 48.4 ± 51.9* 11.9 ± 63.2 0.994 0.334
Men 27.9 ± 59.5 16.6 ± 58.9 18.1 ± 40.9* 0.013 0.048
Genotype interaction
LA 21.4 ± 77.7 35.2 ± 74.8 16.7 ± 29.5 0.359 0.150
NA 22.4 ± 46.9 22.6 ± 45.1 0.0 ± 62.8 0.438 0.433
iNOS
All participants 5.0 ± 38.3 36.7 ± 82.6* 19.7 ± 62.4 0.734 0.007
Women 16.9 ± 28.8 56.1 ± 109.4 2.3 ± 24.1 0.897 0.303
Men 2.7 ± 41.2 29.9 ± 71.3 27.5 ± 70.4 0.470 0.019
Genotype interaction
LA 6.3 ± 36.2 17.0 ± 66.9 33.0 ± 52.4 0.299 0.091
NA 4.7 ± 38.1 46.2 ± 26.7 10.4 ± 69.6 0.996 0.080
eNOS
All participants 11.7 ± 65.6 34.9 ± 72.2* 8.2 ± 50.2 0.509 0.035
Women 13.2 ± 71.7 42.2 ± 42.1* 14.7 ± 48.8 0.997 0.565
Men 12.9 ± 65.5 26.4 ± 83.7 20.5 ± 49.4 0.351 0.115
Genotype interaction
LA 4.8 ± 54.9 28.9 ± 77.8 16.2 ± 62.6 0.910 0.344
NA 28.3 ± 72.9 34.8 ± 74.6 0.2 ± 44.8 0.536 0.334
VEGFA
All participants 14.3 ± 58.1 32.2 ± 69.7* 6.2 ± 45.2 0.398 0.045
Women 12.6 ± 59.0 30.4 ± 68.9 3.0 ± 61.6 0.533 0.112
Men 9.4 ± 55.4 26.2 ± 67.9 10.0 ± 36.3* 0.870 0.500
Genotype interaction
LA 26.3 ± 65.9 19.4 ± 75.6 3.0 ± 40.6 0.497 0.665
NA 7,7 ± 57.6 27.7 ± 60.1 1.1 ± 46.5 0.896 0.256
Changes are expressed as mean ± SD (N ¼ 32). WW, white wine; WW þ Tyr, white wine plus tyrosol (Tyr) capsules; LA, low
activity group metabolizers; NA, normal activity group metabolizers. CD40L, CD40 ligand; CFH, complement factor H; eNOS,
endothelial nitric oxide synthase 3; iNOS, inducible nitric oxide synthase; p65/RELA, transcription factor p65 (RELA); VEGFA,
vascular endothelial growth factor. ANOVA adjusted by age and sex. *P < 0.05, yP < 0.001 versus its baseline; P value, significance
for inter-intervention comparisons.
A. Boronat et al. / Data in brief 27 (2019) 104787 9TaqMan allelic discrimination system (Applied Biosystems, Foster City, CA, USA). Copy-number vari-
ations (CYP2A6 *4, *12, and CYP2D6 *5, and duplications) were analyzed with specific copy number
assays. When these allelic variants were not detected, a designation of *1 (e.g. wildtype) was assigned.
2.3.1. SNP genotyping
Table 3 shows the characteristics of CYP2A6 and CYP2D6 tested allelic variants. The following SNPs
were analyzed: for CYP2A6 *2 and *9, and for CYP2D6 *2, *4, *9, *10, *35, and *41. TaqMan SNP geno-
typing assay were used, which included FAM™ and VIC™ dye-labeled TaqMan pre-designed proves
Fig. 3. Comparison of the effects of white wine (WW) (blue) versus those of white wine plus tyrosol (WW þ Tyr) (Green), CD40L,
CD40 ligand; NF-KB, nuclear factor kappa B; CFH, complement factor H; iNOS, inducible nitric oxide synthase; eNOS, endothelial
nitric oxide synthase.
A. Boronat et al. / Data in brief 27 (2019) 10478710specifics for each SNP. PCR was performed in a QuantStudio™ 12K Flex Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Reactions were prepared with 10 ng of DNA, 0.25 mL of TaqMan SNP
Genotyping Assay, and 2.5 mL of TaqMan Genotyping Master Mix (Applied Biosystems, Foster City, CA,
USA). SNP determinationwasmade using allelic discrimination plots with TaqMan Genotyper Software
(Applied Biosystems, Foster City, CA, USA).2.4. Copy number variation (CNV) detection analysis
TaqMan CNV assays were used to analyze CYP2A6 allelic variants *4, *12 (Hs07545274_cn;
Hs07545275_cn), and CYP2D6 allelic variants *5 (deletion),*1xN, *2xN, and *35xN (Hs00010001_cn).
Real time qPCR was performed using the specific TaqMan assays. Quantitative PCR was performed in
QuantStudio™ 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, USA). Reaction was
carried in 384-well plates with a mixture of TaqMan Master Mix (Applied Biosystems, Foster City, CA,
USA), CNV assays, 10 ng DNA/well and RNase P as reference (Applied Biosystems, Foster City, CA, USA).
Reactions were performed in duplicates. Copy number calls were made with the Expression Suite
Software v1.0.3 (Applied Biosystems, Foster City, CA USA). CYP2D6 gene duplications as previously
described [5]. First, a specific 6.6 kb long piece of CYP2D6was amplified. Second, a 3.5 kb fragment was
amplified from alleles carrying gene duplications. Every duplication-positive sample was further
analyzed using two long-range PCR reactions that allow to discriminate among CYP2D6*1xN, *2xN, and
*4xN duplications to determine allele-defining SNPs.2.5. Polygenic activity score
Tested allelic variants were categorized into: those with no-function (CYP2A6 *2, *4; CYP2D6 *4,*5);
decreased function (CYP2A6 *9,*12; CYP2D6 *9,*10,*11); normal function (CYP2A6 *1; CYP2D6 *1,*2,*35);
and increased function (CYP2A6 *1xN; CYP2D6 *1xN,*2xN,*35xN). A score of 0, 0.5, 1 or 2 was assigned
for the presence of each allele (Table 4). For each enzyme, an activity score was given to each volunteer
according to the identified alleles and classified as detailed above based on the method described by
Gaedigk et al. [6]. A pooled polygenic activity score (PAS) was calculated by adding together the activity
A. Boronat et al. / Data in brief 27 (2019) 104787 11scores of both enzymes. Finally, according to their PAS, individuals were placed into three groups of
predicted activity: low (LA), normal (NA), and rapid activity (RA) groups.
2.6. Endothelial function measurement
Endothelial function was assessed before and after interventions by monitoring endothelium-
mediated changes (reactive hyperemia index, RHI) in the digital pulse waveform, known as the Pe-
ripheral Arterial Tone (PAT) signal (EndoPAT 2000; Itamar Medical Inc., Caesarea, Israel). Specially
designed finger probes were placed on the middle finger of each subject's dominant hand. The probes
comprised a system of inflatable latex air cuffs connected by pneumatic tubes to an inflating device
controlled through a computer algorithm. A constant counter pressure (pre-determined by baseline
DBP) was applied through the air cushions. Pulsatile volume changes of the distal digit induced
pressure alterations in the finger cuff, which were sensed by pressure transducers and transmitted to
and recorded by the EndoPAT 2000 device. EndoPAT 2000 also provides the augmentation index (AI), a
measurement of arterial stiffness via pulse-wave analysis, which was normalized to 75 bpm heart rate.
Measurements were performed by a trained professional with the participants in resting supine
conditions, in a quiet room at a constant temperature after 10 minutes of stabilization. Hyperemic
reactivity index measured by EndoPAT 2000 has been shown to predict cardiovascular disease [7].
2.7. Gene expression measurements
On the basis of their relationship with endothelial health and atherosclerosis, and the available data
of gene expression response after VOO ingestion several candidate genes were selected. Candidate
genes were AKT serine/threonine kinase 2 (AKT2), arachidonate 5-lipoxygenase (ALOX5), CD40 ligand
(CD40L), complement factor H (CFH), endothelial nitric oxide synthase 3 (eNOS), endothelial plas-
minogen activator inhibitor (SERPINE1), inducible nitric oxide synthase (iNOS), interferon gamma
(IFNG), interleukins (IL)1B (IL1B) and 6 (IL6), matrixmetalloproteinases (MMP) 2 (MMP2) and 9 (MMP9),
mitogen-activated protein kinase 14 (MAPK14), monocyte chemoattractant protein 1 (MCP1), nuclear
factor (NF) (erythroid-derived 2)-like 2 (NEF2L2), NF-kappa B inhibitor alpha (NFKBIA), platelet-derived
growth factor subunit B (PDGFB), peroxisome proliferator-activated receptor alpha (PPARɑ), sirtuins
(SIRT) 1 (SIRT1), 2 (SIRT2), and 6 (SIRT6), transcription factor p65 (p65/RELA), tumor necrosis factor
alpha (TNF-ɑ), and vascular endothelial growth factor (VEGFA). Glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) and B-actin were used as endogenous controls to correct changes in gene
expression. Isolation of RNA from PBMCwas performedwith the RNeasy Mini Kit (Qiagen, Duesseldorf,
Germany). DNA complementary conversionwas then carried out with the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA).
Gene expression was measured, before and after interventions, by a real-time polymerase chain
reaction with a QuantStudio™ 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA) and SYBR Green dye-based analysis. Samples were analyzed in duplicate. Results were obtained
with the Expression Suite Software v1.0.3 (Applied Biosystems, Foster City, CA, USA). Changes in gene
expression were assessed first by calculating the relative quantification, applying the 2eDDCT of each
sample. Thereafter, the fold change of each interventionwas extracted by calculating the ratio between
values at the end and at baseline of each intervention period.
2.8. Sample size and power analyses
A total sample of 32 participants would allow at least 80% power to detect a statistically significant
difference among groups of 0.205 units in the RHI measurement, assuming a dropout rate of 5% and
type I error of 0.005 (2-sided). The standard deviation of the measurement was assumed 0.4 [7].
2.9. Statistical analyses
Normality of continuous variables was assessed by normal probability plots and data were log
transformed when required. Intra-treatment comparisons were assessed by Student's t-test for paired
A. Boronat et al. / Data in brief 27 (2019) 10478712samples. Comparisons among treatments were made by an ANOVA for repeated measures and
adjusted by age, gender, smoking, AAS medication, and baseline concentrations. In the case of lipids an
additional adjustment for LDL cholesterol values at the beginning of the clinical trial was performed. A
general lineal model was used to assess linear and quadratic trends. For the post-hoc pairwise com-
parison, the Tuckey test was used. Statistical analyses were performed with R (R Foundation for Sta-
tistical Computing, Vienna, Austria). version 3.0.2., and R package multcomp. Significance was defined
as p < 0.05.
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